Synergism between AT1 receptor and hyperhomocysteinemia during vascular remodeling

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 12, 2007, Pages 1771-1776

  Sen, Utpal ^a   Herrmann, Markus ^b   Herrmann, Wolfgang ^b   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Angiotensin II type 1 (AT1) receptor; Collagen type 1; Extracellular matrix; Extracellular signal regulated kinase 1 2 (ERK 1 2); Matrix metalloproteinase 9 (MMP 9); Signal transducer and activator of transcription 3 (STAT3)

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; COLLAGEN TYPE 1; GELATINASE B; HOMOCYSTEINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT3 PROTEIN; VALSARTAN;

ANIMAL CELL; CONFERENCE PAPER; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HYPERHOMOCYSTEINEMIA; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION;

ANIMALS; BLOOD VESSELS; BLOTTING, WESTERN; CELLS, CULTURED; COLLAGEN TYPE I; ENDOTHELIUM, VASCULAR; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; MATRIX METALLOPROTEINASE 9; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; RECEPTOR, ANGIOTENSIN, TYPE 1; STAT3 TRANSCRIPTION FACTOR;

EID: 36849026088     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.354     Document Type: Conference Paper

References (34)

1. Refsum H, Ueland P, Nygard O, Vollset, O. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62.
2. Sen U, Moshal KS, Tyagi N, Kartha GK, Tyagi SC. Homocysteine-induced myofibroblast differentiation in mouse aortic endothelial cells. J Cell Physiol 2006;209:767-74.
3. Moshal KS, Sen U, Tyagi N, Henderson B, Steed M, Ovechkin AV, et al. Regulation of homocysteine-induced MMP-9 by extracellular regulated protein kinase-1/2 (ERK-1/2) pathway. Am J Physiol Cell Physiol 2006;290:C883-91.
4. Eto H, Biro S, Miyata M, Kaieda H, Obata H, Kihara T, et al. Angiotensin II type 1 receptor participates in extracellular matrix production in the late stage of remodeling after vascular injury. Cardiovasc Res 2003;59:200-11.
5. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997;95:1119-21.
6. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006;5:4.
7. Kuroki M, O'Flaherty JT. Extracellular signal-regulated protein kinase (ERK)-dependent and ERK-independent pathways target STAT3 on serine-727 in human neutrophils stimulated by chemotactic factors and cytokines. Biochem J 1999;341:691-6.
8. Zhang H, Sun GY. Expression and regulation of AT1 receptor in rat lung microvascular endothelial cell. J Surg Res 2006;134:190-7.
9. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499-513.
10. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 2003;9:594-600.
11. Smith GR, Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm 2004;1:3.
12. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003;2:1139-47.
13. Lentz, SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemos 2005;3:1646-54.
14. Morel JC, Park CC, Zhu K, Kumar P, Ruth JH, Koch AE. Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J Biol Chem 2002;277:34679-91.
15. Tharaux PL, Chatziantoniou C, Fakhouri F, Dussaule JC. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension 2000;36:330-6.
16. Ford CM, Li S, Pickering JG. Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation. Arterioscler Thromb Vasc Biol 1999;19:1843-51.
17. Mujumdar VS, Hayden MR, Tyagi SC. Homocyst(e)ine induces calcium second messenger in vascular smooth muscle cells. J Cell Physiol 2000;183:28-36.
18. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995;274:1049-57.
19. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
20. Selhub J. Homocysteine metabolism. Annu Rev Med 1999;19:217-46.
21. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci 1994;91:6369-73.
22. Charpiot P, Bescond A, Augier T, Chareyre C, Fraterno M, Rolland PH, et al. Hyperhomocysteinemia induces elastolysis in minipig arteries: structural consequences, arterial site specificity and effect of captopril- hydrochlorothiazide. Matrix Biol 1998;17:559-74.
23. Dzau VJ. Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-52.
24. Katwa LC, Sun Y, Campbell SE, Tyagi SC, Dhalla AK, Kandala JC, et al. Pouch tissue and angiotensin peptide generation. J Mol Cell Cardiol 1998;30:1401-13.
25. Sun Y, Weber KT. Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. Ann Med 1998;1:3-8.
26. Medina M, Urdiales JL, Amores-Sanchez MI. Roles of homocysteine in cell metabolism: old and new functions. Eur J Biochem 2001;268:3871-82.
27. Plucinska K, Kataoka T, Yodo M, Cody WL, He JX, Humblet C, et al. Multiple binding modes for the receptor-bound conformations of cyclic AII agonists. J Med Chem 1993;36:1902-13.
28. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci 2004;101:10602-7.
29. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-5.
30. Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993;8:395-405.
31. Nagata T, Kai H, Shibata R, Koga M, Yoshimura A, Imaizumi T. Oncostatin M, an interleukin-6 family cytokine, upregulates matrix metalloproteinase-9 through the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cultured smooth muscle cells. Arterioscler Thromb Vasc Biol 2003;23:588-93.
32. Rocnik EF, Chan BM, Pickering JG. Evidence for a role of collagen synthesis in arterial smooth muscle cell migration. J Clin Invest 1998;101:1889-98.
33. Rodriguez-Barbero A, Obreo J, Yuste L, Montero JC, Rodriguez-Pena A, Pandiella A, et al. Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts. FEBS Lett 2002;513:282-8.
34. Kassab S, Garadah T, Abu-Hijleh M, Golbahar J, Senok S, Wazir J, et al. The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats. J Renin Angiotensin Aldosterone Syst 2006;7:206-11.